Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03205046 · ClinicalTrials.gov registry record · Phase 1
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
A Phase 1 study, sponsored by Acerta Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT03205046: Clinical Trial Phase 1 study, sponsored by Acerta Pharma.
NCT03205046 is a Phase 1 study that was terminated before completion, run by Acerta Pharma. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03205046, a Phase 1 study, was terminated before completion, sponsored by Acerta Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study evaluates the safety of acalabrutinib and vistusertib when taken in combination.
Primary Outcome
Safety assessments comprised type, frequency, severity, and relationship to either or both study drug of any AEs or abnormalities of laboratory tests; serious adverse events (SAEs); dose-limiting toxicities (DLTs); or AEs that led to dose modification, dose delay, or discontinuation of study drug(s).
Interventions
- DRUG acalabrutinib
- DRUG vistusertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-06-29 |
| Est. Completion | 2019-11-20 |
| Phase | Phase 1 |
Why NCT03205046 stopped before completion
NCT03205046 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 2 interventions - of which acalabrutinib is the first listed.
NCT03205046 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03205046 about?
NCT03205046 is a clinical study titled "A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies". This study evaluates the safety of acalabrutinib and vistusertib when taken in combination.
What is the current status of trial NCT03205046?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2017-06-29. Estimated completion is 2019-11-20.
What interventions are being tested in trial NCT03205046?
The interventions under investigation include: acalabrutinib (DRUG), vistusertib (DRUG).
Who is sponsoring clinical trial NCT03205046?
This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03205046's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI